Cancer research startup HiberCell has taken lab space at Taconic Investment Partners and Silverstein Properties’ 619 West 54th Street on the Far West Side, the landlords told Commercial Observer.
The new biotech company is the first of its kind to focus on dormant disseminated cancer cells—meaning cells that have spread from the initial tumor or cancer site—and their role in cancer relapse. HiberCell just launched with $61 million in Series A venture capital funding, from investors that included Arch Venture Partners and the city-backed NYC Life Sciences Fund.
“Recurrence of cancer, which is the cause of many cancer deaths, is driven by dormant disseminated tumor cells that remain undetected in the body for long periods of time,” the company noted in a press release. “HiberCell is working to develop first-in-class drugs that target DTCs that originate from solid and liquid tumors.”
Read the full story in Commercial Observer